secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001232524-25-000073
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharma Q3 rev $1.13B (+7%), GAAP EPS $4.08, adj. EPS $8.13; FY25 rev guid narrowed
--------------------------------------------------------------------------------

- Total revenues $1.126B (+7% YoY); GAAP net income $251M, non-GAAP adj. net income $501M.
- Epidiolex sales grew 20% to $302.6M; Xywav sales grew 11% to $431.4M; Modeyso launch contributed $11.0M.
- Zepzelca + atezolizumab combo approved for 1L maintenance ES-SCLC; NCCN inclusion.
- Saniona licensing agreement for SAN2355, a Kv7.2/7.3 activator for epilepsy and other indications.
- FY2025 total revenue guidance narrowed to $4.175-$4.275B from $4.150-$4.300B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000123252425000073/0001232524-25-000073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000123252425000073/jazz-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001232524-25-000073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer